SSMT-2026-0012 — Intermittent pneumatic compression accelerates recovery and improves s

SSMT-2026-0012v12026-07-26 Type O · Outcome Wearables & Recovery draft

Claim, as marketed

“Recover faster. Train harder tomorrow.”

Canonical claim

Intermittent pneumatic compression accelerates recovery and improves subsequent performance after exercise.

Scope

Intermittent pneumatic compression devices, 20–30 minutes at 70–200 mmHg post-exercise.

Verdict

Partially supported Accurate about how you feel; unsupported about what you can then do.

Real evidence, narrower than the claim.

Claim drift — 4 of 7

–Population–Setting▲Comparator▲Outcome▲Magnitude▲Reproducibility–Independence

Independence is aligned and unusually so — the one verified vendor-funded trial was itself null on performance. Convergence across funding sources is the strongest signal in this file.

Evidence located

−0.45

soreness ES (n=554)

0.089

muscle function g at 72h

0/8

trials showing performance benefit

6/17

used a placebo

Findings

Subjective — small, real, replicated. Pooled soreness Hedges' g 0.486 (95% CI 0.117–0.855) at 0–2h and 0.368 (0.045–0.691) at 96h across 17 studies (n=319). A second independent meta-analysis of 27 studies (n=554) found pain/soreness ES −0.45 (−0.65 to −0.25). Feeling less sore is a legitimate outcome and users are not imagining it.

Objective — consistently null. Pooled muscle function runs g = 0.243 → 0.134 → 0.117 → 0.089 at 0–2h, 24h, 48h and 72h, with every confidence interval crossing zero. Note the direction: the effect shrinks toward zero exactly as the horizon approaches 'tomorrow', which is the horizon the marketing occupies.

Not one of eight primary trials found a between-group performance benefit — including a 161-km ultramarathon RCT (n=72) and a vendor-funded trial where isokinetic peak torque returned P>0.350.

Blinding is the load-bearing weakness. Only 6 of 17 studies used any placebo; 35% blinded participants; none reported allocation concealment or blinding of assessors. No trial reported a blinding-integrity check or measured expectancy. Compression is felt, so sham participants generally know.

The telling pattern. The subjective benefit narrows or disappears as blinding improves. A 2026 placebo-controlled trial in elite U19 footballers found no group difference even on self-reported soreness (p=0.089–0.834).

Why reproducibility drifts. The soreness effect is timepoint-unstable — significant at 0–2h and 96h but not at 24h, 48h or 72h. That pattern is more consistent with noise than with a biological dose-response.

What would change this verdict

An adequately powered (n≥100), sham-controlled, preregistered trial showing a significant between-group improvement in a hard performance outcome at 24–48h, replicated independently. Downward: two or three further well-blinded trials replicating the finding that even the subjective benefit vanishes against placebo.

Practitioner read

Recovery boots reliably make people feel less sore for a day or so after hard training, and that is a real measured effect — not nothing, especially if feeling better keeps an athlete consistent. But across every trial that measured it, athletes using boots did not jump higher, sprint faster or lift more the next day than athletes who did nothing. Treat them as a comfort and adherence tool, not a performance intervention, and do not let them displace sleep and food.

Could not be verified

One published meta-analysis reports a confidence interval that does not contain its own point estimate (CK: ES 0.36, CI 0.37–0.68) — a likely source typo. Do not cite that figure.
Funding not located for four items; silence was not treated as independence.
One vendor's marketing page describes a study's authors in terms suggesting company affiliation while the paper declares no COI. Unresolved — check directly before grading that study either way.

Listed rather than dropped. Counts are floors, not censuses.

Sources

Maia F, et al. (2024). Biol Sport 41(4):263–275 — SR/meta-analysis, 17 studies ↗
Maia F, et al. (2025). Int J Sports Physiol Perform 20(8) — placebo-controlled RCT ↗
Wiecha S, et al. (2021). BMC Sports Sci Med Rehabil — sham-controlled, n=45 ↗
Haun CT, et al. (2017). PLoS ONE 12(6):e0180429 — vendor-funded, null on performance ↗
Hoffman M, et al. (2016). JOSPT 46(5):320–326 — n=72 ultramarathon ↗
BMC Sports Sci Med Rehabil (2026), PMID 41656279 — placebo-controlled, elite U19 ↗

Every source must resolve at a DOI or PubMed ID.

Changelog

v1 · 2026-07-26 · Initial grade.

Cite this card

SSMT. "Intermittent pneumatic compression accelerates recovery and improves subsequent performance after exercise." Claim SSMT-2026-0012 v1, graded 2026-07-26. https://sportssciencetech.com/c/SSMT-2026-0012

Disagree with this grade? Every card carries “what would change this verdict” so the specification is explicit. Send evidence and it will be logged and the card re-versioned in public — including when it moves a grade in a manufacturer's favour. Submit evidence →